title: The safety and efficacy of different doses of bacillus Calmette Guérin in superficial bladder transitional cell carcinoma.
abstract: OBJECTIVE
  To conduct a trial using three different doses of bacillus Calmette-Guérin (BCG) to determine whether lowering the dose of BCG could reduce toxicity without compromising its efficacy in the treatment of superficial bladder cancer.
  
  
  METHODS
  From July 2002 to June 2005, 152 patients with superficial bladder cancer entered the trial. The patients were randomized to receive three different doses of BCG: 40, 80, and 120 mg. There were no significant differences in clinical and pathologic characteristics among the three groups. Twenty-four patients could not be followed to the end of the study because of poor compliance. At completion of the study, 40 patients could be evaluated in group A (40 mg), 48 in group B (80 mg), and 40 in group C (120 mg).
  
  
  RESULTS
  After treatment patients were evaluated for a mean follow-up period of 36 months (range 18 to 52 months). No significant difference in recurrence rate (20% versus 25% versus 20% respectively; P >0.05) was observed among the groups, and no progression of the disease was seen. Significant differences were observed among groups A, B, and C in local toxicity (30% versus 41.7% versus 70%, respectively; P <0.01). Systemic toxicity was more common in group C compared with groups B and A (P <0.01).
  
  
  CONCLUSIONS
  Reduction in the dose of intravesical BCG can reduce the toxicity associated with the treatment of superficial bladder cancer without affecting the efficacy of therapy.
authors.affiliation: Division of Urology, Department of Surgery, S. N. Medical College, Agra, India. dr.madhu.agra@gmail.com
authors.forename: Madhu S
authors.initials: MS
authors.lastname: Agrawal
authors.forename: Moneet
authors.initials: M
authors.lastname: Agrawal
authors.forename: Sumit
authors.initials: S
authors.lastname: Bansal
authors.forename: Mayank
authors.initials: M
authors.lastname: Agarwal
authors.forename: Prashant
authors.initials: P
authors.lastname: Lavania
authors.forename: Jitendra
authors.initials: J
authors.lastname: Goyal
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000009:adverse effects; D000283:Administration, Intravesical; D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000009:adverse effects; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine